What can we expect from raloxifene in the treatment of postmenopausal osteoporosis: Gynaecological point of view;Co můžeme očekávat od raloxifenu při léčbě postmenopauzální osteoporózy - Pohled gynekologa

Ceska Gynekologie

Volumn 67, Issue 4, 2002, Pages 187-191

  Chmel, R ^a   Rob, L ^a   Strnad, P ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Breast cancer; Cardiovascular disease; Endometrial cancer; Osteoporosis; Postmenopause; Raloxifene; SERM

Indexed keywords

ESTROGEN; GESTAGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CARCINOMA; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH STATUS; HUMAN; HYSTERECTOMY; LEIOMYOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RISK FACTOR; THROMBOSIS; TREATMENT PLANNING; UTERUS BLEEDING; ESTROGEN THERAPY; MIDDLE AGED;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 2242482895     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: Impact of breast cancer risk
2. Compliance of women taking estrogen replacement therapy
3. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
4. American Society of Clinical Oncology technology assessment on the breast cancer risk reduction strategies: Tamoxifene and raloxifene
5. Characterization of hot flushes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials
6. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60
7. Endometrial changes with tamoxifene: Comparison between tamoxifentreated and nontreated asymptomatic, postmenopausal breast cancer patients
8. The effect of raloxifene on risk of breast cancer in postmenopausal women
9. Adverse events reported by postmenopausal women in controlled trials with raloxifene
10. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women
11. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
12. Selective estrogen receptor modulation: The search for an ideal hormonal therapy for breast cancer
13. Tamoxifen for early breast cancer: An overview of the randomized trials
14. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
15. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
16. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women
17. Drugs for the gynecologist to prescribe in the prevention of breast cancer: Current status and the future trends
18. Raloxifene effect on frequency of surgery for pelvic floor relaxation
19. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
20. The effect of the antiestrogen on the bone mineral density in normal late postmenopausal women
21. Adherence to postmenopausal hormone therapy during the year after the initial prescription: A population-based study
22. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
23. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
24. Effects of raloxifene treament on uterine leiomyomas in postmenopausal women
25. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: A 2-year randomized, placebo-controled, comparative study
26. Randomized, double blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilatation in postmenopausal women
27. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: A placebo-controlled randomized trial
28. Prevalence osteoporózy v České republice
29. Reducing the risk of breast cancer with tamoxifen in women at increased risk
30. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women